electroCore, Inc. ECOR
Nasdaq · XNAS · stock · Electromedical & Electrotherapeutic Apparatus
Chart by TradingView
3/9
Piotroski F — financial health
-36.67
Altman Z″ — distress risk · distress
—
Dividend payout · no dividend
Financials (annual, from 10-K)
| FY | Revenue | Net income | Gross profit | Free cash flow | Equity |
|---|---|---|---|---|---|
| 2025 | $32.0M | -$14.0M | $27.8M | -$8.3M | -$1.7M |
| 2024 | $25.2M | -$11.9M | $21.4M | — | $7.5M |
| 2023 | $16.0M | -$18.8M | $13.2M | $14.5M | $7.4M |
| 2022 | $8.6M | -$22.2M | $7.0M | — | $17.1M |
| 2021 | $5.5M | -$17.2M | $4.1M | — | $36.6M |
| 2020 | $3.5M | -$23.5M | $1.8M | — | $23.6M |
Why these scores methodology →
Piotroski F-score: 3/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: -36.67 (distress)
- Working capital / assets 0.231
- Retained earnings / assets -10.235
- EBIT / assets -0.705
- Equity / liabilities -0.084
Source: SEC EDGAR filings · CIK 0001560258 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.